Plus Therapeutics, Inc. PSTV
Set alert
At close · Jul 31
After hours · Jul 31, 4:00 PM ET
- YTD
- -69.65%
- 1 year
- -58.16%
- Open
- 3.65
- Prev close
- 3.87
- Mkt cap
- 9.36M
- Vol
- 96.53K
- Avg vol
- 116.51K
- EPS
- -2.30
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.62
- High
- 3.94
- Forward P/E
- -0.52
- Beta
- 0.69
- Short ratio
- 0.98
- Inst. own
- 11.39%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.29
- 200-d avg
- 1.63
- 1y target
- 15.75
Key statistics
- Market cap
- 6.31M
- Enterprise value
- 1.90M
- Trailing P/E
- 0.00
- Forward P/E
- -0.52
- PEG ratio
- 0.00
- Price / sales
- 1.15
- Price / book
- 0.00
- EPS (TTM)
- -2.37
- Beta
- 0.69
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -240.15%
- Revenue (TTM)
- 5.51M
- Revenue growth
- -31.00%
- Free cash flow
- -1.10M
- Total cash
- 8.44M
- Total debt
- 3.43M
- Return on equity
- 0.00%
- Shares outstanding
- 5.90M
- Short % of float
- 0.90%
- 50-day average
- 1.29
- 200-day average
- 1.63
Analyst view
Consensus: none
- Target (low)
- 4.00
- Target (mean)
- 15.75
- Target (high)
- 32.00
- Strong buy2
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.5125.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.46 | -0.46 | 0.00 | 0.00% |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -0.71 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -0.75 | — | — |
| Mar 5, 2024 | Dec 1, 2023 | -0.78 | -0.70 | +0.08 | +10.26% |
| Oct 31, 2023 | Sep 1, 2023 | -0.58 | -1.00 | -0.42 | -72.41% |
| Aug 14, 2023 | Jun 1, 2023 | -1.91 | -0.59 | +1.32 | +69.11% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 9, 2024 | Ascendiant Capital | main | Buy | Buy |
| Nov 26, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 15, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 14, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About Plus Therapeutics, Inc.
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- plustherapeutics.com
News
- Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For Monday
- 12 Health Care Stocks Moving In Friday's Intraday Session
- This Rockwell Automation Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Benzinga Bulls And Bears: TSMC, Rocket Lab, J.B. Hunt — And Space Stocks Soar
- Crude Oil Gains Over 1%; US Retail Sales Rise 0.6% In November
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Nasdaq Falls Over 100 Points; Bank of America Posts Upbeat Earnings
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Why Gelteq Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket
Your note
Sign in to keep a note on PSTV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CLOWES HOWARD | Director | Purchase | Sep 10, 2024 | 26,497 |
| HAWKINS RICHARD JAMES | Director | Purchase | Sep 12, 2024 | 0 |
| HEDRICK MARC HAMILTON | Chief Executive Officer | Purchase | Sep 9, 2024 | 20,425 |
| LENK ROBERT P | Director | Purchase | May 7, 2024 | 29,327 |
| PETERSEN GREG B | Director | Purchase | Sep 10, 2024 | 48,921 |
| SIMS ANDREW JOHN HUGH MACINTYRE | Chief Financial Officer | Purchase | Sep 9, 2024 | 9,815 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AIGH Capital Management LLC | 9.51% | 560,905 | 600.17K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.92% | 54,274 | 58.07K | Sep 29, 2024 |
| Vanguard Group Inc | 0.55% | 32,541 | 34.82K | Sep 29, 2024 |
| Ashton Thomas Private Wealth, LLC | 0.22% | 12,913 | 13.82K | Sep 29, 2024 |
| Blackrock Inc. | 0.12% | 6,960 | 7.45K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.06% | 3,709 | 3.97K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.60% | 35,470 | 37.95K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.55% | 32,541 | 34.82K | Sep 29, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.15% | 8,899 | 9.52K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.14% | 8,280 | 8.86K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.09% | 5,315 | 5.69K | Oct 30, 2024 |